Sugi Predict

Sugi Predict / Compounds / SCHEMBL6661328

SCHEMBL6661328

SCHEMBL6661328

COCCOCCOCCN1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ACKR3 P25106 3/20 0.42
▸ CHRM2 P08172 1/20 0.42
▸ CHRM4 P08173 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ EPHX2 P34913 7/20 0.42
▸ HSD11B1 P28845 1/20 0.42
▸ TLR8 Q9NR97 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ KMT5A Q9NQR1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15352136 1.00 USP2 (0.44) USP2SMN1; SMN2ACKR3CHRM2CHRM4
SCHEMBL22262696 1.00 USP2 (0.44) USP2SMN1; SMN2ACKR3CHRM2CHRM4
SCHEMBL2225547 0.91 HSD11B1 (0.49) USP2SMN1; SMN2ACKR3CHRM2CHRM4
SCHEMBL28703997 0.90 EPHX2 (0.47) USP2SMN1; SMN2ACKR3CHRM2CHRM4
SCHEMBL25678515 0.88 TLR8 (0.46) USP2SMN1; SMN2ACKR3CHRM2CHRM4
SCHEMBL15435945 0.88 SMN1; SMN2 (0.44) USP2SMN1; SMN2ACKR3CHRM2CHRM4
SCHEMBL25905171 0.88 SMN1; SMN2 (0.44) USP2SMN1; SMN2ACKR3CHRM2CHRM4
SCHEMBL6135079 0.88 EPHX2 (0.47) USP2SMN1; SMN2ACKR3CHRM2CHRM4
SCHEMBL6134639 0.88 EPHX2 (0.47) USP2SMN1; SMN2ACKR3CHRM2CHRM4
SCHEMBL23251655 0.88 USP2 (0.46) USP2SMN1; SMN2ACKR3CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313572-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2025-10-09 — — US disclosed
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2024-07-11 — — US disclosed
US-20230399340-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2023-12-14 — — US disclosed
US-10865186-B2 Opioid agonists and uses thereof NEKTAR THERAPEUTICS (US) 2020-12-15 — — US disclosed
US-10865186-B2 Opioid agonists and uses thereof NEKTAR THERAPEUTICS (US) 2020-12-15 — — US disclosed
CN-111818916-A Macrocyclic MCL-1 inhibitors and methods of use 艾伯维公司 2020-10-23 — — CN disclosed
US-20200239494-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2020-07-30 — — US disclosed
EP-3074379-B1 OPIOID AGONISTS AND USES THEREOF NEKTAR THERAPEUTICS INDIA PVT LTD (IN) 2019-06-26 — — EP disclosed
EP-3074379-B1 OPIOID AGONISTS AND USES THEREOF NEKTAR THERAPEUTICS INDIA PVT LTD (IN) 2019-06-26 — — EP disclosed
US-20180362468-A1 OPIOID AGONISTS AND USES THEREOF NEKTAR THERAPEUTICS 2018-12-20 — — US disclosed
US-20170066782-A1 DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE NEKTAR THERAPEUTICS 2017-03-09 — — US disclosed
US-20170022167-A1 OPIOID AGONISTS AND USES THEREOF NEKTAR THERAPEUTICS 2017-01-26 — — US disclosed
US-20170022167-A1 OPIOID AGONISTS AND USES THEREOF NEKTAR THERAPEUTICS 2017-01-26 — — US disclosed
US-20170022167-A1 OPIOID AGONISTS AND USES THEREOF NEKTAR THERAPEUTICS 2017-01-26 — — US disclosed
EP-3074379-A1 OPIOID AGONISTS AND USES THEREOF Nektar Therapeutics (India) Pvt. Ltd. (IN) 2016-10-05 — — EP disclosed
WO-2015079459-A1 OPIOID AGONISTS AND USES THEREOF NEKTAR THERAPEUTICS (INDIA) PVT.LTD. (IN) 2015-06-04 — — WO disclosed
EP-1082138-B1 TEXAPHYRIN CONJUGATES AND USES THEREOF UNIV TEXAS (US) 2004-08-25 — — EP disclosed
US-6207660-B1 Texaphyrin conjugates and uses thereof PHARMACYCLICS, INC. 2001-03-27 — — US disclosed
EP-1082138-A1 TEXAPHYRIN CONJUGATES AND USES THEREOF THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2001-03-14 — — EP disclosed
WO-1999062551-A1 TEXAPHYRIN CONJUGATES AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1999-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022167-A1 OPIOID AGONISTS AND USES THEREOF OPRM1, OPRK1, OPRD1 USP2 4290/4885SMN1; SMN2 1006/4885ACKR3 273/4885
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 USP2 2815/4885SMN1; SMN2 605/4885ACKR3 2018/4885
US-20180362468-A1 OPIOID AGONISTS AND USES THEREOF OPRM1, OPRK1, OPRD1 USP2 4290/4885SMN1; SMN2 1006/4885ACKR3 273/4885
US-20200239494-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 USP2 2815/4885SMN1; SMN2 605/4885ACKR3 2018/4885
US-20250313572-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 USP2 2815/4885SMN1; SMN2 605/4885ACKR3 2018/4885
US-10865186-B2 Opioid agonists and uses thereof OPRM1, OPRK1, OPRD1 USP2 4290/4885SMN1; SMN2 1006/4885ACKR3 273/4885
US-20170066782-A1 DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE KCNJ2, TRPC5, RYR2 USP2 4243/4885SMN1; SMN2 3458/4885ACKR3 3574/4885
US-20230399340-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 USP2 2815/4885SMN1; SMN2 605/4885ACKR3 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.